199 related articles for article (PubMed ID: 36865165)
1. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; Jeong AD; Guntupalli SR; Behbakht K; Gbaja V; Arnoult N; Chuong EB; Bitler BG
bioRxiv; 2023 Feb; ():. PubMed ID: 36865165
[TBL] [Abstract][Full Text] [Related]
2. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
Mol Cancer Ther; 2024 May; ():. PubMed ID: 38714351
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
[TBL] [Abstract][Full Text] [Related]
4. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
O'Brien S; Butticello M; Thompson C; Wilson B; Wyce A; Mahajan V; Kruger R; Mohammad H; Fedoriw A
BMC Cancer; 2023 Aug; 23(1):775. PubMed ID: 37596538
[TBL] [Abstract][Full Text] [Related]
6. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
7. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
8. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
10. Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.
Besschetnova A; Han W; Liu M; Gao Y; Li M; Wang Z; Labaf M; Patalano S; Venkataramani K; Muriph RE; Macoska JA; Siegfried KR; Evans J; Balk SP; Gao S; Han D; Cai C
Cancer Res Commun; 2023 Aug; 3(8):1716-1730. PubMed ID: 37663929
[TBL] [Abstract][Full Text] [Related]
11. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
12. Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.
Ang GCK; Gupta A; Surana U; Yap SXL; Taneja R
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740522
[TBL] [Abstract][Full Text] [Related]
13. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.
Carter J; Hulse M; Sivakumar M; Burtell J; Thodima V; Wang M; Agarwal A; Vykuntam K; Spruance J; Bhagwat N; Rager J; Ruggeri B; Scherle P; Ito K
Cancer Res Commun; 2023 Nov; 3(11):2233-2243. PubMed ID: 37861290
[TBL] [Abstract][Full Text] [Related]
14. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
15. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of learning and memory by Drosophila EHMT/G9a.
Kramer JM; Kochinke K; Oortveld MA; Marks H; Kramer D; de Jong EK; Asztalos Z; Westwood JT; Stunnenberg HG; Sokolowski MB; Keleman K; Zhou H; van Bokhoven H; Schenck A
PLoS Biol; 2011 Jan; 9(1):e1000569. PubMed ID: 21245904
[TBL] [Abstract][Full Text] [Related]
19. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
Nakamura T; Kajihara N; Hama N; Kobayashi T; Otsuka R; Han N; Wada H; Hasegawa Y; Suzuki N; Seino KI
J Gynecol Oncol; 2023 May; 34(3):e25. PubMed ID: 36603850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
